Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)

Br J Haematol. 2022 Jul;198(1):203-206. doi: 10.1111/bjh.18198. Epub 2022 Apr 21.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological* / therapeutic use
  • Chronic Disease
  • Hodgkin Disease* / drug therapy
  • Hodgkin Disease* / pathology
  • Humans
  • Neoplasm Recurrence, Local / drug therapy
  • Nivolumab / therapeutic use

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab